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Aims: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT),
patient reported outcome and describe levels of glycated hemoglobin and its association
with the effects on visual acuity in patients treated with anti-VEGF for visual impairment
due to diabetic macular edema (DME) during 12 months in a real world setting.
Methods: In this cross-sectional study, 58 patients (29 females and 29 males; mean age,
68 years) with type 1 and type 2 diabetes diagnosed with DME were included. Medical data
and two questionnaires were collected; an eye-specific (NEI VFQ-25) and a generic health-
related quality of life questionnaire (SF-36) were used.
Results: The total patient group had significantly improved visual acuity and reduced reti-
nal thickness at 4 months and remains at 12 months follow up. Thirty patients had signif-
icantly improved visual acuity, and 27 patients had no improved visual acuity at 12 months.
The patients with improved visual acuity had significantly improved scores for NEI VFQ-25
subscales including general health, general vision, near activities, distance activities, and
composite score, but no significant changes in scores were found in the group without
improvements in visual acuity.
Conclusions: Our study revealed that anti-VEGF treatment improved visual acuity and cen-
tral retinal thickness as well as patient-reported outcome in real world 12 months after
treatment start.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).77 80 80.
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1.1. Diabetes and vision loss
Both type 1 and type 2 diabetes mellitus are major causes of
vision loss [1]. Diabetic retinopathy (DRP) is a general term
for vascular changes that occur in the retina that may become
sight-threatening and require treatment [2]. Diabetic macular
edema (DME) is a result of vascular changes close to the mac-
ula leading to swelling of the central retina in the macula and
may induce vision loss [3–5]. Vision loss is the complication of
diabetes [6] that affects the person’s quality of life the most
[7]. Almost every person with type 1 diabetes and more than
half of the persons with type 2 diabetes develop some degree
of diabetic retinopathy [8]. Many persons with diabetes do not
have regular eye examinations, although it is known that
early diagnosis and treatment of sight-threatening retinopa-
thy reduce the risk of blindness [9]. In Sweden there is a
screening program for diabetic retinopathy with fundus pho-
tography but the proportion of fundus examinations has
decreased in recent years [10]. Early and regular screening
for retinopathy is important in preventing retinopathy at an
early stage [11].
1.2. Patient reported outcomes
In recent years, the relationship between patient-reported
outcomes such as visual function and health-related quality
of life has attracted attention worldwide [12,13]. It has been
previously reported that visual impairment affects patient’s
reported outcomes [14–17]. Persons with diabetic retinopathy
are more likely to have negative feelings about diabetes than
persons without DRP [18]. These negative feelings may have
negative effects on patient reported outcome [14,19]. Vision
loss due to diabetes can also affect the person’s perception
of their ability to function independently [20]. Therefore, it
is of outmost importance to target the early stages of DRP to
inhibit its progression, to prevent the disease from reaching
a level that has severe impact on a person’s quality of life
[21,22]. Persons with decreased visual acuity related to dia-
betic macular edema have rated their general health as rela-
tively low [23], and have been associated with prior
development of retinopathy and neuropathy, with decreased
vision [24]. Overall, patient reported outcomes reflect the
emotional impact of treatment and the impact of diabetes
retinopathy on their quality of life [25].
1.3. Effect of treatment with anti-vascular endothelial
growth factor (VEGF)
Anti-VEGF drugs have revolutionized the treatment of
reduced vision due to DME [26,27]. Intravitreal treatment is
generally initiated with monthly injections until visual acuity
is stabilized. Additional treatmentmay be given depending on
visual acuity and/or presence of macular edema on optical
coherence tomography (OCT) [27]. Anti-VEGF treatment is
capable of improving vision instead of merely stabilizing thecondition [28,29]. Several studies have reported that ranibizu-
mab improves patient-reported visual function [15,30–34],
which can be stabilized for long periods of time [17].
Since 2011, intravitreal administration of anti-VEGF drugs
for sight-threatening DME has been a part of routine clinical
care in Sweden. We have previously reported baseline data
from a cohort of patients [23]. To further examine objective
visual acuity and patient-reported outcome measurements
in a real world setting, meaning that data were collected in
routine clinical care. It is also important to study this patient
group over time. In this study, data from a 12 months follow
up is reported in relation to baseline data.
Aims:
 To evaluate objective visual acuity measured with ETDRS
and retinal thickness using optical coherence tomography
(OCT) at 4 and 12 months after treatment start.
 To evaluate patient-reported outcomes measurements,
visual functioning (NEI VFQ-25), and health-related quality
of life (SF-36).
 To describe the progress regarding levels of glycated hemo-
globin (HbA1c) and its association with visual acuity
(ETDRS).
2. Materials and methods
2.1. Subjects
This is a follow-up study where baseline data have been pre-
viously reported [23]. Participants were males and females
over 18 years of age. All participants had visual impairment
due to DME and received intravitreal treatment with ranibizu-
mab (Lucentis). Data collection started in May 2012 and was
terminated in February 2015 at two county hospitals in
Sweden.
2.2. Ethical considerations
This study was approved by the Regional Ethical Review Board
of Uppsala, Sweden, and was conducted in accordance with
the Declaration of Helsinki. All participants gave their written
consent before study entry [23]. Participants were informed
that they could terminate their participation at any time.
2.3. Clinical assessment
Visual acuity was measured using either the ETDRS letter
chart (number of letters) at a distance of 2 m, or using the
Snellen chart at 5 m. The ETDRS letter chart was used for eyes
treated with anti-VEGF [2]. The initial eye examination
included measurement of best-corrected visual acuity with
the ETDRS or Snellen chart, slit-lamp examination of the
anterior segment, intraocular pressure measurement, fundus
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(Topcon Corporation, Tokyo, Japan).
Glycated haemoglobin (HbA1c) are reported in derived
NGSP units (%) followed by The International Federation of
Clinical Chemistry (IFCC) reference method (mmol/mol).
Initially, the patients received three monthly injections.
Thereafter they were examined once a month and received
additional injections if required. When a steady state was
reached in the eye, examinations were conducted less fre-
quently. Additional intravitreal treatments were given at the
physician’s discretion in cases of unstable or reduced visual
acuity and/or increased edema on OCT. Each eye was
assessed individually and that the patient could receive treat-
ment in the better-seeing eye, in the worse-seeing eye, or in
both eyes. Five-letters improvement in visual acuity mea-
sured with ETDRS was considered as clinically significant,
meaning that the improvement was perceptible to the
patient.
All patients received two questionnaires, the National Eye
Institute Visual Functioning Questionnaire 25 (NEI VFQ-25)
and the Short Form -36 Health Survey (SF-36), at baseline, 4
and 12 months after treatment start. The questionnaires were
sent to the patients by mail with a reply envelope attached. A
reminder, which included a new questionnaire, was posted
after 2–3 weeks if needed.
2.4. Patient reported outcomes measurements
The National Eye Institute Visual Functioning Questionnaire
25 (NEI VFQ-25) is a validated, eye-specific questionnaire that
provides a subjective perception of one’s own visual function-
ing [35] and has been used to assess visual functioning in sev-
eral studies [15,32,36]. The questionnaire has been validated
for Swedish-speaking persons [37] and consists of 25 ques-
tions divided into 11 vision-related subscales: general vision,
ocular pain, near activities, distance activities, social func-
tioning, mental health, role difficulties, dependency, driving,
color vision, and peripheral vision. The questionnaire also
includes a single item measuring general health and a com-
posite score calculation [35,38].
The Short Form-36 Health Survey (SF-36) is a measure of
health-related quality of life [39]. SF-36 measures eight
parameters of health-related quality of life: physical function,
role functioning (physical limitations), bodily pain, general
health, vitality, social function, role functioning (emotional
limitations), and mental health. The SF-36 has been validated
and translated into Swedish [40].
2.5. Data analyses
SPSS, version 22 for Windows (SPSS, Chicago, IL, USA) was
used for statistical analyses. The manual for NEI VFQ-25
was used in calculating the scale conversions, and calcula-
tions of subscale and composite scores [41]. Analyses were
conducted with one treated eye per person and the worse-
seeing eye was excluded when a person received anti-
VEGF treatment in both eyes. Descriptive statistics were
used for presenting patient demographics and characteris-
tics. Linear regression analyses were used to examine which
variable contributed most to visual acuity ETDRS scores. Thet-test was used to examine differences in mean changes
over time regarding objective measurements involving
HbA1c, OCT, and ETDRS scores. A t-test was also used to
identify changes in self-rated visual functioning (NEI VFQ-
25) and self-reported health-related quality of life (SF-36).
A value of p < 0.05 was considered statistically significant.
The population was divided into two groups based on their
change in ETDRS scores 12 months after the first anti-VEGF
injection. One group of patients improved their ETDRS
scores by more than five letters, which was considered clin-
ically significant, and the other group which did not improve
their ETDRS scores.3. Results
3.1. Study subjects
As previously described, we enrolled 59 patients in this study
at baseline [23]. One person declined participation at the first
follow-up at 4 months after the first injection. In total, 58 per-
sons completed the study at the 1 year follow-up.
3.2. Patient characteristics
Table 1 shows characteristics of the total patient population.
The patient sample was divided into two groups, 12 months
after treatment start, involving persons with improved and
unimproved visual acuity. The group without improved
ETDRS was treated with insulin to a larger extent compared
with the group with improvements in their visual acuity
(not significant). In the group that showed an improvement
in ETDRS scores, 24 persons received 5–10 injections, in the
group without improvement, 16 persons received the same
number of injections (ns) (Table 1).
3.3. Visual acuity: ETDRS
The visual acuity for the total patient sample was 65.0 letters
(±12.1) at baseline, and showed a significant improvement
after 4 months and remains at 12 months follow-up. The
group with improved visual acuity showed a clinically signif-
icant change in mean ETDRS scores from baseline to the 12-
month follow-up (Table 2).
3.4. Retinal thickness: OCT
The results showed a significant reduction for retinal thick-
ness measured with OCT after 4 months and remains at
12 months follow up for the total patient sample population
(Table 2).
3.5. HbA1c
The total patient sample as well as the two groups with
improved and unimproved ETDRS showed no significant
improvement in HbA1c levels. However, the HbA1c levels
decreased from 8, 8% (73 mmol/mol) to 8.1% (65 mmol/mol)
(not significant) in the group with no ETDRS improvement.
The t-test showed that the group with unimproved ETDRS
Table 1 – Patient characteristics.
Total patient sample (n = 58)a Improved ETDRS (n = 30) Unimproved ETDRS (n = 27)
n n n
Female/Male 29/29 16/14 13/14
Age (mean, range) 68 (45–86) 69 (45–86) 68 (49–83)
Type of diabetes
Type 1 5 2 3
Type 2 53 28 24
Diabetes treatment
OAD (Oral antidiabetic agents) 14 8 6
Insulin 21 9 15
OAD and insulin 22 12 9
Number of visits (mean, range) 14 (10–19) 14 (11–19) 14 (10–19)
Number of injections (mean, range) 5 (1–10) 5 (3–10) 5 (2–8)
1–2 2 0 1
3–4 16 6 10
5–6 27 18 9
7–8 12 5 7
9–10 1 1 0
Laser treatments
0 44 21 22
1 9 6 3
2 5 3 2
Visual impairment baseline
Normal 26 11 14
Mild 23 13 10
Moderate/severe 6 4 2
Visual impairment at 12 months
Normal 26 13 12
Mild 25 13 12
Moderate/severe 5 3 2
a One person was diagnosed with secondary neovascular glaucoma and vitreous hemorrhage and was excluded.
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cantly greater ETDRS scores at baseline than the group with
improvements (Table 2).
Linear regression analyses showed that the changes in
visual acuity ETDRS scores could be explained individually
by HbA1c baseline (r2 = 0.11, p = 0.08) and HbA1c delta
(r2 = 0.13, p = 0.06) and when they were combined (r2 = 0.14,
p = 0.013).Table 2 – Change from baseline to 12 months.
Total sample Improv
Variables Mean SD t-value p-value Mean
HbA1c* Baseline 8.3 (67) 16 1.312 0.195 8.0 (64)
1 year 8.0 (64) 17 7.9 (63)
OCT Baseline 403 122 6.524 0.001 428
1 year 282 83 276
ETDRS Baseline 65.0 12.1 4.361 0.000 60.7
1 year 70.2 11.1 72.1
SD, standard deviation; HbA1c, glycated hemoglobin; OCT, optical cohere
* HbA1c – NGSP (%), IFCC (mmol/mol).3.6. Patients with clinically reduced visual acuity at 12
months
Of the patients with unimproved ETDRS values over time,
eight persons had clinically reduced (P5 letters) their visual
acuity (see Table 3). The mean age of these patients was
72.5 years (SD 5.4), and they had a mean number of 14 visits,
with a mean number of 5 intravitreal injections.ed ETDRS Unimproved ETDRS
SD t-value p-value Mean SD t-value p-value
14 0.054 0.958 8.8 (73) 18.4 1.710 0.103
14 8.1 (65) 19.9
136 5.445 0.000 373 98 3.886 0.001
68 289 99
13.1 9.973 0.000 69.9 8.8 1.727 0.096
11.2 68.0 10.7
nce tomography; ETDRS, visual acuity.
Table 3 – Characteristics of patients with decreased visual
acuity (n = 8).
Variables Mean SD t-value p-value
HbA1c* Baseline 9.4 (79) 26 2.353 0.065
1 year 7.0 (53) 4
OCT Baseline 390 141 2.061 0.078
1 year 275 63
ETDRS Baseline 68.6 11.8 6.799 0.000
1 year 59.5 12.7
SD, standard deviation; HbA1c, glycated hemoglobin; OCT, optical
coherence tomography; ETDRS, visual acuity.
* HbA1c – NGSP (%), IFCC (mmol/mol).
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decrease of 5–9 letters in their ETDRS scores, two persons
had a decrease of 10–14 letters, and one patient lost more
than 15 letters at 12 months. The HbA1c levels showed a ten-
dency to decrease from baseline to the 12 months follow-up
in this group (see Table 3).
One person had decreased general condition nausea, vom-
iting, and difficulty breathing at the 4-month follow-up visit
and was referred to the emergency room. This person had
renal failure, asthma, and a previous pulmonary embolism
that was assessed as not related to the anti-VEGF-treatment
for macular edema. Another patient fell and contracted a sub-
dural bleeding, which required surgery. This patient received
several laser treatments in both eyes with no improvement in
visual acuity during the study period.
Two other patients suffered from macular edema relapses
that caused deterioration, and were instead treated with ster-
oids. We could not identify any distinctive characteristic of
the other patients that could explain the deterioration of their
visual acuities.
3.7. Patient-reported visual function: NEI VFQ-25
The result from paired t-test showed a significant improve-
ment from baseline to 4 months; general health (p = 0.004),
general vision (p = 0.001), near activities (p = 0.10), mental
health (p = 0.013) and composite score (p = 0.020), there wereTable 4 – NEI-VFQ-25 at baseline, 4 months and 12 months.
Subgroup VFQ-25 Baseline (mean, SD)
General health 36.70 (22.02)
General vision 61.18 (18.94)
Ocular pain 84.72 (20.70)
Near activities 66.36 (21.41)
Distance activities 73.46 (24.94)
Social functioning 87.26 (19.99)
Mental health 76.50 (21.31)
Role difficulties 79.40 (23.18)
Dependency 93.43 (18.86)
Driving 74.66 (35.17)
Color vision 91.62 (19.05)
Peripheral vision 76.82 (24.18)
Composite score 78.30 (16.75)no significant improvement between 4 and a 12 months
follow-up (Table 4).
Table 5 shows a significant improvement in the total
patient population from baseline to 1 year for general health
(p = 0.002), general vision (p = 0.001), near activities
(p = 0.015), and distance activities (p = 0.026). Furthermore,
when the cohort was divided into two groups based on ETDRS
changes at 12 months, the group with improved ETDRS scores
also showed significant improvements in general health
(p = 0.004), general vision (p = 0.000), near activities
(p = 0.015), and distance activities (p = 0.008). The group with
no improvements in visual acuity showed no significant
improvements in the NEI VFQ-25 subscales (Table 4). General
vision (p = 0.004) was the only subscale that showed a signif-
icant difference in mean change between the groups.
3.8. SF-36
The SF-36 subscales showed no significant improvement
(data not shown).
4. Discussion
This study shows the results from patients receiving anti-
VEGF treatment for DME in an unselected population in a
real-world setting at two eye clinics in Sweden. Approxi-
mately 50% of the patients improved their visual acuity after
4 months and remains at 12 months, which is consistent with
other studies [15,33,42]. The general health measured with
NEI VFQ-25 improved from baseline as seen in other studies
[15,34], although there were low scores for baseline values
[23].
The total sample population had significantly improved
ETDRS scores and OCT results. When the study sample was
divided into two groups, one group with improved visual acu-
ity and the other group with no improvements in visual acu-
ity, some differences were found between the groups. Visual
acuity in the group with improved ETDRS scores measured
a lower scores at baseline which can indicate the treatment
outcome result as shown in the present study in line with ear-
lier results [15,17]. The group with improved visual acuity
comprised a larger percentage of patients with five to six4 month (mean, SD) 12 month (mean, SD)
47.16 (23.01) 47.81 (21.88)
67.36 (14.36) 67.84 (15.01)
87.50 (16.59) 88.73 (17.11)
71.55 (18.73) 72.92 (20.76)
77.21 (23.58) 79.55 (21.59)
89.25 (17.50) 89.62 (18.63)
83.58 (14.25) 81.64 (17.86)
80.36 (22.24) 78.01 (21.85)
93.37 (15.02) 90.87 (21.47)
75.00 (33.00) 75.68 (35.10)
86.74 (23.48) 92.46 (16.69)
80.10 (21.03) 79.92 (24.90)
81.04 (15.01) 81.17 (15.91)
Table 5 – Change in NEI VFQ-25, baseline to 1 year.
Total sample Improved ETDRS Unimproved ETDRS
Subscales VFQ-25 Mean SD t-value p-value Mean SD t-value p-value Mean SD t-value p-value
General health Baseline 36.70 22.02 3.359 .002 37.50 24.45 3.186 .004 36.36 20.01 1.547 .137
1 year 46.81 21.88 51.04 18.77 43.18 24.62
General vision Baseline 61.18 18.94 3.485 .001 57.69 19.04 4.573 .000 65.83 18.16 .327 .747
1 year 67.84 15.01 69.23 14.12 66.67 16.33
Ocular pain Baseline 84.72 20.70 1.801 .077 80.36 23.92 1.548 .133 90.50 15.00 .609 .548
1 year 88.89 17.11 85.27 20.43 92.50 11.97
Near activities Baseline 66.36 21.41 2.517 .015 63.39 18.75 2.596 .015 69.67 24.40 .868 .394
1 year 72.92 20.76 71.88 20.24 73.33 21.78
Distance activities Baseline 73.46 24.94 2.299 .026 72.47 23.61 2.849 .008 74.00 27.14 1.033 .312
1 year 79.55 21.59 79.76 21.48 79.17 22.57
Social functioning Baseline 87.26 19.99 1.347 .184 86.57 17.99 1.140 .265 87.50 22.53 .749 .461
1 year 89.62 18.63 89.35 16.52 89.50 21.25
Mental health Baseline 76.50 21.31 1,906 .062 76.12 22.31 1.573 .127 78.00 20.26 .784 .440
1 year 81.64 17.86 82.89 16.72 80.50 19.63
Role difficulties Baseline 79.40 23.18 .643 .523 79.91 22.40 1.045 .305 79.00 24.93 .161 .873
1 year 78.01 21.85 76.79 19.75 78.50 24.35
Dependency Baseline 93.43 18.62 .818 .417 97.22 6.54 1.028 .314 89.58 26.15 .285 .779
1 year 90,87 21.47 92.90 20.11 88.19 23.43
Driving Baseline 74.66 35.17 .269 .789 75.69 36.25 .186 .855 72.92 35.94 .294 .772
1 year 75.68 35.10 77.08 33.55 73.61 38.32
Color vision Baseline 91.62 19.05 .299 .766 92.59 13.54 .700 .490 90.24 24.11 .046 .964
1 year 92.46 16.69 94.44 12.66 90.00 20.41
Peripheral vision Baseline 76.92 24.18 1.087 .282 75.93 26.39 1.546 .134 78.13 2250 .259 .798
1 year 79.92 24.90 80.56 23.34 79.42 2752
Composite score Baseline 78.30 16.75 2.115 .039 77.27 15.74 2.400 .024 79.57 18.37 .516 .611
1 year 81.17 15.91 81.32 15.10 80.71 17.33
SD, standard deviation.
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treatments. Before the anti-VEGF treatment started, this
patient group had lower HbA1c levels and ETDRS scores but
a higher degree of retinal thickness.
Linear regression analyses showed that variations in
visual acuity could be correlated with the levels of HbA1c
and change in HbA1c after anti-VEGF treatment. This is con-
sistent with a consensus document regarding appropriate
management of diabetic macular edema by an expert panel
[43]. In a study with a smaller patient population, similar
results to our study were reported, although the patients
had higher HbA1c levels at baseline [44]. It is noteworthy, that
both studies reflect real world conditions. In contrast, post
hoc analysis from the RIDE/RISE study [15,45] reported that
HbA1c levels at baseline did not affect the treatment out-
comes. In these large clinical studies, a good glycemic control
is an inclusion criterion. While in real life studies, the
included patients can suffer from poorly controlled diabetes
and high level of HbA1c. We found the greatest decrease in
HbA1c levels at 1 year follow-up in the group of eight subjects
that experienced worsening of ETDRS. Taken together, the
findings may indicate that a high initial HbA1c followed by
a rapid drop may be associated with a risk for less beneficial
outcomes of anti-VEGF treatment. It is important to further
examine the factors that can affect the outcome of treatment
[46], such as glycemic control, visual acuity, degree of macular
edema [47] or blood pressure control.
The cohort in this study exhibited low general health
before starting the anti VEGF-treatment [23], lower than in
other studies [15,32,34]. Knowing that these patients demon-
strated low general health is important as it can enable the
health care system to develop and provide relevant support
and information. An important point is that regular eye
screening in Sweden has decreased during the last year [10].
The cause of the decline is unknown. It is well known that
regular eye examinations/screening are essential for detect-
ing eye complications at an early stage, when the condition
can be monitored and treated to preserve vision. This study
emphasizes the importance of regular eye screening to iden-
tify and treat vision-threatening complications and maintain
a good health-related quality of life.
After one year, the patients who improved their visual acu-
ity also improved the score for several key subscales of the
NEI VFQ-25 which is in line with other [17]. These patients
experienced an improved general health, better visual acuity
and found it easier to observe objects at near and far dis-
tances. It can be assumed that this is useful for patients in
their everyday life. In contrast, the patients in present study
did not improve the composite score which has been demon-
strated in another study [15].
Within the group of patients with no improvements in
visual acuity, we identified eight persons with decreased
visual acuity. This group of patients had a higher mean age,
higher HbA1c levels, and slightly higher OCTat baseline com-
pared with the rest of the group with unimproved ETDRS.
There was a decrease in HbA1c levels in these patients,
although it was not significant. Previous studies have
reported that a rapid decrease in HbA1c levels can cause dam-
age [48], and can affect subsequent anti-VEGF treatment [44].
Although the number of patients was small and it was notpossible to reach significant conclusions, it is nonetheless
important to mention that additional studies are needed
regarding this patient group. A closer cooperation between
the ophthalmologists and the diabetes physician could be
beneficial, for example to optimize HbA1c levels in a con-
trolled and individualized manner before starting anti-VEGF
treatment for DME.
The result of the SF-36 survey showed that none of the
subscales showed significant improvements at any time.
These observations emphasize the importance of using
disease-specific measurements for this patient group [49].
Regarding limitations of this study, it comprised a rela-
tively small sample size. It is however important to empha-
size that this patient group received anti-VEGF treatment
for DME in a real-world setting in Sweden, where it is a com-
mon treatment option.
In conclusion, findings in this real-world study of long-
term outcomes of anti-VEGF-treatment showed that the
patient-reported outcome significantly improved in the total
patient population. The results also indicate the role of HbA1c
at baseline and the treatment effects in ETDRS scores. How-
ever, additional studies are needed to address the long-term
effects of these parameters on DME.Conflict of interest
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